 |
InterPro: IPR004554 Hydroxymethylglutaryl-CoA reductase, class I, catalytic
Protein matches
|
UniProtKB Matches: 343 proteins |
|
Accession
|
IPR004554 HMG_CoA_Rdtase_I_cat |
Type
|
Domain |
Signatures
|
|
InterPro Relationships
|
|
Parent
|
IPR002202 Hydroxymethylglutaryl-CoA reductase, class I/II, catalytic
|
|
Found in
|
IPR004816 Hydroxymethylglutaryl-CoA reductase, class I, metazoan
|
|
Contains
|
IPR009023 Hydroxymethylglutaryl-CoA reductase, class I/II, NAD/NADP-binding
IPR009029 Hydroxymethylglutaryl-CoA reductase, class I/II, substrate-binding
|
GO Term annotation
|
|
Process
|
GO:0008299 isoprenoid biosynthetic process
GO:0055114 oxidation reduction
|
|
Function
|
GO:0004420 hydroxymethylglutaryl-CoA reductase (NADPH) activity
GO:0050661 NADP or NADPH binding
|
|
Component
|
GO:0016021 integral to membrane
|
|
InterPro annotation
|
|
Entry Details in BioMart
|
Abstract
|
Synonym(s): 3-hydroxy-3-methylglutaryl-coenzyme A reductase, HMG-CoA reductase.
There are two distinct classes of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase enzymes: class I consists of eukaryotic and most archaeal enzymes (EC:1.1.1.34), while class II consists of prokaryotic enzymes (EC:1.1.1.88) [1, 2].
Class I HMG-CoA reductases catalyse the NADP-dependent synthesis of mevalonate from 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA). In vertebrates, membrane-bound HMG-CoA reductase is the rate-limiting enzyme in the biosynthesis of cholesterol and other isoprenoids. In plants, mevalonate is the precursor of all isoprenoid compounds [2]. The reduction of HMG-CoA to mevalonate is regulated by feedback inhibition by sterols and non-sterol metabolites derived from mevalonate, including cholesterol. In archaea, HMG-CoA reductase is a cytoplasmic enzyme involved in the biosynthesis of the isoprenoids side chains of lipids [3]. Class I HMG-CoA reductases consist of an N-terminal membrane domain (lacking in archaeal enzymes), and a C-terminal catalytic region. The catalytic region can be subdivided into three domains: an N-domain (N-terminal), a large L-domain, and a small S-domain (inserted within the L-domain). The L-domain binds the substrate, while the S-domain binds NADP.
Class II HMG-CoA reductases catalyse the reverse reaction of class I enzymes, namely the NAD-dependent synthesis of HMG-CoA from mevalonate and CoA [4]. Some bacteria, such as Pseudomonas mevalonii, can use mevalonate as the sole carbon source. Class II enzymes lack a membrane domain. Their catalytic region is structurally related to that of class I enzymes, but it consists of only two domains: a large L-domain and a small S-domain (inserted within the L-domain). As with class I enzymes, the L-domain binds substrate, but the S-domain binds NAD (instead of NADP in class I).
This entry represents the catalytic region found in class I HMG-CoA reductase enzymes (the eukaryotic enzymes contain an extra N-terminal domain not represented by this entry).
|
Structural links
|
|
Database links
|
|
Example proteins
|
P04035 3-hydroxy-3-methylglutaryl-coenzyme A reductase
P12683 3-hydroxy-3-methylglutaryl-coenzyme A reductase 1
P14773 3-hydroxy-3-methylglutaryl-coenzyme A reductase
P14891 3-hydroxy-3-methylglutaryl-coenzyme A reductase 1
Q01237 3-hydroxy-3-methylglutaryl-coenzyme A reductase
More proteins
Example Proteins Key
| InterPro entry accession number/name and structure databases |
Colour code |
| IPR009023 |
Hydroxymethylglutaryl-CoA reductase, class I/II, NAD/NADP-binding |
 |
| IPR004554 |
Hydroxymethylglutaryl-CoA reductase, class I, catalytic |
 |
| IPR002202 |
Hydroxymethylglutaryl-CoA reductase, class I/II, catalytic |
 |
| IPR000731 |
Sterol-sensing 5TM box |
 |
| IPR009029 |
Hydroxymethylglutaryl-CoA reductase, class I/II, substrate-binding |
 |
| IPR004816 |
Hydroxymethylglutaryl-CoA reductase, class I, metazoan |
 |
|
SWISS-MODEL |
 |
|
PDB Chain |
 |
|
ModBase |
 |
|
SCOP Domain |
 |
|
CATH Domain |
 |
|
Additional Reading
|
|
Park WK, Kennedy RM, Larsen SD, Miller S, Roth BD, Song Y, Steinbaugh BA, Sun K, Tait BD, Kowala MC, Trivedi BK, Auerbach B, Askew V, Dillon L, Hanselman JC, Lin Z, Lu GH, Robertson A, Sekerke C.
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
Bioorg. Med. Chem. Lett. 18 2008 1151-6
[PubMed: 18155906]
http://dx.doi.org/10.1016/j.bmcl.2007.11.124
|
|
Istvan ES, Deisenhofer J.
Structural mechanism for statin inhibition of HMG-CoA reductase.
Science 292 2001 1160-4
[PubMed: 11349148]
http://dx.doi.org/10.1126/science.1059344
|
|
Pfefferkorn JA, Choi C, Larsen SD, Auerbach B, Hutchings R, Park W, Askew V, Dillon L, Hanselman JC, Lin Z, Lu GH, Robertson A, Sekerke C, Harris MS, Pavlovsky A, Bainbridge G, Caspers N, Kowala M, Tait BD.
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.
J. Med. Chem. 51 2008 31-45
[PubMed: 18072721]
http://dx.doi.org/10.1021/jm070849r
|
|
Pfefferkorn JA, Choi C, Song Y, Trivedi BK, Larsen SD, Askew V, Dillon L, Hanselman JC, Lin Z, Lu G, Robertson A, Sekerke C, Auerbach B, Pavlovsky A, Harris MS, Bainbridge G, Caspers N.
Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors.
Bioorg. Med. Chem. Lett. 17 2007 4531-7
[PubMed: 17574411]
http://dx.doi.org/10.1016/j.bmcl.2007.05.097
|
|
Pfefferkorn JA, Song Y, Sun KL, Miller SR, Trivedi BK, Choi C, Sorenson RJ, Bratton LD, Unangst PC, Larsen SD, Poel TJ, Cheng XM, Lee C, Erasga N, Auerbach B, Askew V, Dillon L, Hanselman JC, Lin Z, Lu G, Robertson A, Olsen K, Mertz T, Sekerke C, Pavlovsky A, Harris MS, Bainbridge G, Caspers N, Chen H, Eberstadt M.
Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors.
Bioorg. Med. Chem. Lett. 17 2007 4538-44
[PubMed: 17574412]
http://dx.doi.org/10.1016/j.bmcl.2007.05.096
|
|